Press Releases


July 12, 2021
Caribou Biosciences Announces Dosing of First Patient in Phase 1 Clinical Trial Evaluating CB-010, a CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy, in Patients with Relapsed or Refractory B Cell Non-Hodgkin Lymphoma

June 22, 2021
Caribou Biosciences Appoints Scott Braunstein, M.D. to Board of Directors

May 17, 2021
Caribou Biosciences Announces Appointment of Katy Rezvani, M.D., Ph.D. and Christopher Sturgeon, Ph.D. to its Scientific Advisory Board

May 5, 2021
Caribou Biosciences Announces Appointment of Industry Leader Andrew Guggenhime to its Board of Directors

March 8, 2021
Caribou Biosciences to Participate in Three Upcoming Investor Conferences in March

March 3, 2021
Caribou Biosciences Raises $115M Series C Financing to Advance Next-Generation CRISPR Technologies and Allogeneic Cell Therapy Pipeline

February 10, 2021
AbbVie and Caribou Biosciences Announce Collaboration and License Agreement for CAR-T Cell Products

February 9, 2021
Caribou Biosciences Appoints Jason O’Byrne as Chief Financial Officer


November 18, 2020
Caribou Biosciences Announces Licensing Agreement for scFvs Targeting CD371 to Enable Development of Allogeneic Cell Therapies

October 7, 2020
Caribou Biosciences Co-Founder Dr. Jennifer Doudna Awarded Nobel Prize in Chemistry

September 8, 2020
Caribou Biosciences Announces FDA Clearance of its IND for CB-010, an Off-the-shelf Allogeneic Anti-CD19 CAR-T Cell Therapy

May 11, 2020
Caribou Biosciences Appoints Cherry Thomas, MD as Senior Vice President of Clinical Development

May 7, 2020
Caribou Biosciences and MaxCyte Enter into Clinical and Commercial License Agreement

February 19, 2020
Caribou Biosciences and ProMab Biotechnologies Announce Sale and Assignment Agreement for Humanized scFv Targeting BCMA


November 18, 2019
Caribou Biosciences Announces New Methods to Harness Type I CRISPR-Cas Systems for Genome Engineering in Human Cells

September 26, 2019
Caribou Biosciences Announces that JAMS panel issued Interim Award in the arbitration with Intellia Therapeutics

February 12, 2019
Caribou Biosciences Announces Expansion of Scientific Advisory Board


December 12, 2018
Caribou Biosciences Appoints Dr. Natalie Sacks to Board of Directors

September 10, 2018
CRISPR Therapeutics, Intellia Therapeutics and Caribou Biosciences Provide Update on U.S Federal Circuit Decision Upholding the Ruling by U.S. Patent and Trademark Office in Interference Proceeding Relating to CRISPR/Cas9 Genome Editing Technology

June 19, 2018
CRISPR Therapeutics, Intellia Therapeutics, and Caribou Biosciences Announce Grant of U.S. Patent for CRISPR/Cas9 Genome Editing

May 3, 2018
Caribou Biosciences Appoints Timothy F. Herpin, Ph.D. as Chief Business Officer


2017-2014 Press Releases